GLP-1 supply tracker
Current availability for branded GLP-1 medications by dose strength. Compiled from the FDA Drug Shortages database and manufacturer reports.
Last updated: 2026-05-27 · Next refresh weekly · Status reflects editorial review of public data, not real-time pharmacy stock.
Available: 18Limited: 3Shortage: 2Recently resolved: 0
Wegovy
| Dose | Status | Notes |
|---|---|---|
| 0.25 mg | Available | — |
| 0.5 mg | Available | — |
| 1.0 mg | Available | — |
| 1.7 mg | Limited | Some retailers reporting backorders |
| 2.4 mg | Available | — |
Zepbound
| Dose | Status | Notes |
|---|---|---|
| 2.5 mg | Available | — |
| 5 mg | Available | — |
| 7.5 mg | Available | — |
| 10 mg | Available | — |
| 12.5 mg | Limited | Higher-titration doses moving slower |
| 15 mg | Limited | Higher-titration doses moving slower |
Ozempic
| Dose | Status | Notes |
|---|---|---|
| 0.25 mg | Available | — |
| 0.5 mg | Available | — |
| 1.0 mg | Available | — |
| 2.0 mg | Available | — |
Mounjaro
| Dose | Status | Notes |
|---|---|---|
| 2.5 mg | Available | — |
| 5 mg | Available | — |
| 7.5 mg | Available | — |
| 10 mg | Available | — |
| 12.5 mg | Available | — |
| 15 mg | Available | — |
Compounded semaglutide
| Dose | Status | Notes |
|---|---|---|
| All doses | Shortage | FDA proposed removing semaglutide from the 503B bulk list April 30, 2026; 30 warning letters issued; comment period closes June 29, 2026. Access shrinking fast — plan transition to branded. |
Compounded tirzepatide
| Dose | Status | Notes |
|---|---|---|
| All doses | Shortage | Same April 30, 2026 FDA proposal removes tirzepatide from 503B bulk list. Large-scale compounding ending. Transition to branded Zepbound/Mounjaro recommended. |
How to read this tracker
- Available
- No FDA shortage listing, manufacturer confirms full distribution.
- Limited
- Allocation by retailer or zip; expect some pharmacies to be out.
- Shortage
- FDA-listed shortage. Delays of weeks possible. Discuss alternatives with your prescriber.
- Recently resolved
- FDA removed from shortage list within last 6 months. Compounded versions of resolved drugs lose legal compounding-pharmacy access per FDA rules.